Welcome to our dedicated page for OS THERAPIES INCORPORATED news (Ticker: OSTX), a resource for investors and traders seeking the latest updates and insights on OS THERAPIES INCORPORATED stock.
OS Therapies Incorporated (NYSE American: OSTX) is a clinical-stage oncology and biopharmaceutical company focused on osteosarcoma and other solid tumors. News about OS Therapies centers on its listeria-based cancer immunotherapy programs, regulatory interactions, capital markets activity, and the planned spin-off of its veterinary oncology subsidiary, OS Animal Health.
A major theme in OSTX news flow is the progress of OST-HER2 (daznelene lisbac), the company’s lead listeria-based immunotherapy targeting the HER2 protein. Press releases highlight positive Phase 2b data in recurrent, fully resected, pulmonary metastatic osteosarcoma, including statistically significant benefit in 12-month event free survival and reported 2-year overall survival outcomes. The company also reports immune biomarker analyses from its human metastatic osteosarcoma trial and related canine osteosarcoma studies, emphasizing the role of Comparative Oncology and interferon gamma pathway biomarkers as potential surrogate markers of clinical efficacy.
Investors following OSTX news will see regular updates on regulatory milestones, such as FDA Type C and other meetings, waiver of the BLA application fee for OST-HER2, EMA Union Marketing Authorisation eligibility, and preparations for Biologics License Application and Marketing Authorisation Application submissions in the United States, United Kingdom, and European Union. Company outlook releases describe anticipated timelines for regulatory submissions, potential conditional approvals, and planned interactions with FDA, MHRA, and EMA.
OS Therapies also issues news on capital raising and corporate transactions, including warrant exercise inducement agreements, gross proceeds from warrant exercises, and the intended use of proceeds to fund OST-HER2 regulatory and commercial preparation activities and the proposed OS Animal Health spin-off. Additional news items cover the veterinary oncology strategy for canine osteosarcoma, recognition of OST-HER2 in documentaries and awards, and the development of the company’s tunable ADC (tADC) platform.
For readers tracking OSTX, this news feed provides a consolidated view of clinical trial updates, biomarker findings, regulatory developments, financing events, and the evolution of both the human and animal health franchises. Regular visits can help investors and observers monitor how OS Therapies advances OST-HER2 and its broader oncology pipeline through key clinical and regulatory inflection points.
OS Therapies (NYSE-A: OSTX) has announced the pricing of its initial public offering of 1,600,000 shares at $4.00 per share, raising $6.4 million in gross proceeds. The company plans to use the funds to advance its clinical development of OST-HER2 and OST-tADC, two innovative cancer treatments. OST-HER2, their lead product, is in a Phase IIb trial for osteosarcoma with topline data expected in Q4 2024. It has received Rare Pediatric Disease, Fast Track, and Orphan Drug Designations from the FDA and EMA. OST-tADC is a next-generation Antibody Drug Conjugate platform. Trading under the symbol OSTX on the NYSE American is set to begin on August 1, 2024, with the offering closing on August 2, 2024.
OS Therapies (NYSE-A: OSTX) has announced positive safety data from a Phase 1 clinical trial of OST-HER2 in HER2-expressing solid tumors, primarily breast cancer. The trial involved 12 patients, with 10 having breast cancer. The dose selected for the ongoing Phase 2b trial in Osteosarcoma was well-tolerated in breast cancer patients.
Additionally, preclinical efficacy data showed promising results in breast cancer models, including:
- 78% reduction in tumor size
- 33% prevention of breast cancer
- 20% reduction in tumor size when combined with HER2-targeted antibodies
- 65% reduction in metastatic cells in brain metastasis models
OST-HER2 has received Rare Pediatric Disease, Orphan Drug, and Fast Track Designations from the FDA for Osteosarcoma. The company is currently in discussions with the FDA regarding a Breakthrough Therapy designation application based on interim results from their Phase 2b trial.
OS Therapies (NYSE-A: OSTX) announced a positive update from its Phase 2b clinical trial for the immunotherapy OST-HER2 in resected, recurrent osteosarcoma patients. The trial achieved a 1-year event-free survival (EFS) rate of 32.5%, significantly higher than the 20% EFS rate for an unsuccessful comparator. The 1-year and 18-month overall survival (OS) rates were both 90.4%. Importantly, no grade 3, 4, or 5 treatment-related adverse events were reported among the 41 patients. Full enrollment is complete, with primary 12-month EFS and interim 12-month OS data expected by Q4 2024. OST-HER2 aims to prevent metastasis and recurrence while enhancing overall survival.